Astri Therapeutics Inc (ATXS)

(NASDAQ: $ATXS) @AstriaTx partners with Kaken Pharma to bring navenibart, a potential HAE treatment, to Japan with a $16M deal and milestone payments ahead. https://prismmarketview.com/astria-therapeutics-signs-licensing-deal-with-kaken-pharmaceutical-for-hae-treatment-development-in-japan/

$ATXS Release the…Kaken???

$ATXS Added some at $7.25

... courtesy of spmtag. $ATXS $7.17 bid. DAC $7.60. EXIT $14.00. BRIEF: Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for an additional $16 million in total commercialization and sales milestones. In addition to these payments, Astria is also eligible for tiered royalties with the royalty rate as a percentage of net sales up to 30%, and partial Phase 3 cost reimbursement. Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart Phase 3 program. note: Including the upfront payment from Kaken and the expected reimbursement by Kaken of a portion of the Company's Phase 3 program costs, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund its current operating plan into 2028

$ATXS Will get acquired. $15

$ATXS I see $50

$ATXS The hereditary angioedema space is getting crowded with BCRX, KALV, and ATXS. Lordie!

$ATXS "Heads up alert! Upcoming earnings on Friday, 8/8/2025 for $ATXS Bullish (7.2) Astria Therapeutics Inc. (NASDAQ: ATXS) has recently shown promising developments, leading to a positive outlook on its stock. The company, which focuses on therapies for allergic and immunologic diseases, released favorable initial results from its long-term open-label trial of navenibart (STAR-0215) for hereditary angioedema patients, which has the potential to significantly impact their revenue stream if it progresses successfully through subsequent trial phases. The industry average P/E ratio is around 20, and while Astria’s specific P/E ratio is not provided, its promising pipeline and recent developments may positively influence market perception and valuation. EPS growth is expected to be positive, benefiting from potential future revenues from navenibart. While specific revenue forecasts are not detailed, the positive trial results and upcoming presentations at notable summits suggest a strong position in the biopharmaceutical sector. Comparisons to industry peers indicate Astria is maintaining a competitive edge through its innovative approach and focus on niche markets in immunologic diseases. Astria Therapeutics is expected to release its upcoming earnings report soon. Historically, the company has shown a pattern of stable performance, with a focus on research and development expenditures to fuel its pipeline. Analyst consensus estimates suggest a cautious optimism, with expectations centered around advancements in their drug pipeline, particularly navenibart. The potential impact on the stock is significant; positive earnings and developments could drive the stock price higher, especially if milestone achievements are announced. Analysts will be closely watching for updates on trial progress and any strategic partnerships that may enhance market penetration. The biotechnology sector, to which Astria Therapeutics belongs, has shown robust performance overall, driven by innovation and the demand for novel therapies. The sector has experienced moderate growth, with an increasing emphasis on personalized medicine and targeted therapies. Astria’s focus on allergic and immunologic diseases aligns well with current sector trends, potentially positioning it for favorable performance relative to its peers. - Funds were net sellers of $ATXS during the previous reporting quarter. - Funds with large holdings in $ATXS include: - Perceptive Advisors LLC, MV: $35MM. Fund Rank: 61% www.perceptivelife.com - RA Capital Management LLC, MV: $27MM. Fund Rank: 58% www.racap.com - Vivo Capital LP, MV: $8MM. Fund Rank: 57% www.vivocapital.com - Nantahala Capital Management LLC, MV: $4MM. Fund Rank: 67% www.nantahalapartners.com - Adage Capital P, MV: $3MM. Fund Rank: 86% www.adagecapital.com - Last 10 days performance: 8% - Last 30 days performance: 21% - Last 90 days performance: 29% Some of the latest news articles: - Title: Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients Publication Date: 8/1/2025 3:40:42 AM, Source: yahoo URL: https://finance.yahoo.com/news/astria-therapeutics-announces-positive-initial-034042760.html?.tsrc=rss - Title: Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit Publication Date: 7/7/2025 12:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/astria-therapeutics-present-upcoming-2025-120000301.html?.tsrc=rss - Title: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Publication Date: 7/2/2025 8:10:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/astria-therapeutics-announces-inducement-grants-201000423.html?.tsrc=rss - Title: Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit Publication Date: 6/18/2025 12:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/astria-therapeutics-participate-upcoming-oppenheimer-120000001.html?.tsrc=rss Follow us on stocktwits.com. Not a financial advice. Not a trading signal."

$IXHL Blew Phase 2 out of the water: AHI down up to 83% — strong efficacy. Oral sleep apnea treatment = first of its kind. No serious side effects. OSA market = 900M patients globally. CPAP noncompliance = huge unmet need. 💰 Current market cap = ~$83M Meanwhile, look at comps: $ATXS (HAE, Ph2) = $250M $PRAX (CNS, Ph2) = $280M $ARDX (Ph2–3) = $400M+ $TGTX pre-run = $120M → ran 10x post-Ph3 📈 If IXHL starts Phase 3 w/ FDA blessing, re-rating to $200–300M cap is conservative 🔥 Float’s tight. Volume could detonate this.

$ATXS Ok lets get that quad stack!